NCT01739621View on ClinicalTrials.gov

Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Uterine Fibroids
Interventions
DRUG

Proellex 12 mg

DRUG

Proellex 24 mg

All Listed Sponsors
lead

Repros Therapeutics Inc.

INDUSTRY

NCT01739621 - Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200 | Biotech Hunter | Biotech Hunter